A Phase Ib Investigation of Pembrolizumab in Combination with Intratumoral Injection of Clostridium Novyi-NT in Patients with Treatment-Refractory Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Clostridium novyi-NT (Primary) ; Pembrolizumab (Primary) ; Doxycycline
Indications Chordoma; Head and neck cancer; Malignant melanoma; Nasopharyngeal cancer; Solid tumours; Squamous cell cancer; Vulval disorders
Focus Adverse reactions

31 Oct 2024 Planned End Date changed from 1 Oct 2024 to 1 Oct 2026.
31 Oct 2024 Planned primary completion date changed from 1 Oct 2024 to 1 Oct 2026.
18 Apr 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com